PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023

From: Fast Market Research, Inc.
Published: Wed Dec 16 2015


PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023

Summary

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline's (GSK's) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

Full Report Details at
- http://www.fastmr.com/prod/1082867_pharmapoint_human.aspx?afid=301

GlobalData projects the global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare's Triumeq (dolutegravir/abacavir/lamivudine), Gilead's Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead's and Janssen's darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Highlights

Key Questions Answered

* How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2013-2023?
* What are the most promising late-stage pipeline drugs in HIV?
* How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
* What are the unmet needs in HIV treatment management?
* What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Key Findings

* The global HIV therapeutics market was worth approximately $14 billion in 2013, and GlobalData projects this market to reach a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These sales are expected to come predominantly from the US market, as financial austerity measures remain a primary barrier to the growth of the HIV market in the other countries covered in this report.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- EpiCast Report: Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2023
- PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »